allele_iedb stringclasses 95
values | allele stringclasses 95
values | allele_compact stringclasses 95
values | peptide stringlengths 7 15 | peptide_length int64 7 15 | measurement_type stringclasses 2
values | measurement_value float64 0 14.3M | measurement_units stringclasses 1
value | assay_method stringclasses 6
values | assay_response stringclasses 2
values | pubmed_id float64 7.51M 39.2M β | parent_protein stringlengths 3 188 β | protein_accession stringlengths 6 14 | source_organism stringclasses 991
values | source_version stringclasses 2
values | flagged bool 2
classes | self_templated bool 2
classes | has_structures bool 1
class | num_pdbs int64 25 25 | I_sc_best float64 -102.03 -37.97 | I_sc_mean float64 -93.88 60.2 | reweighted_sc_best float64 -733.37 -37.85 | reweighted_sc_mean float64 -705.21 18.9 | total_score_best float64 -623.72 1.04 | total_score_mean float64 -607.3 44 | pdb_dir stringlengths 33 41 | pep_sc_best float64 -42.79 82.3 | pep_sc_mean float64 -39.15 122 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
HLA-B_35_03 | B*35:03 | B3503 | HPNIEEVAL | 9 | IC50 | 6.8 | nM | purified MHC/competitive/radioactivity | half maximal inhibitory concentration (IC50) | 22,508,927 | Genome polyprotein | ACE82359.1 | hepatitis C virus genotype 1a | v1 | false | false | true | 25 | -73.162 | -63.28 | -683.34 | -648.52404 | -585.842 | -565.7758 | structures/B3503/H/HPNIEEVAL.silent | -28.359 | -19.46816 |
HLA-B_35_03 | B*35:03 | B3503 | SPGDLQTLAL | 10 | IC50 | 16,115 | nM | purified MHC/competitive/radioactivity | half maximal inhibitory concentration (IC50) | 22,539,795 | Insulin-1 | NP_032412.3 | Mus musculus | v1 | false | false | true | 25 | -62.861 | -50.62504 | -645.083 | -586.55464 | -568.58 | -529.36148 | structures/B3503/S/SPGDLQTLAL.silent | -14.74 | -6.56832 |
HLA-B_42_01 | B*42:01 | B4201 | SPGDLQTLAL | 10 | IC50 | 35 | nM | purified MHC/competitive/radioactivity | half maximal inhibitory concentration (IC50) | 22,539,795 | Insulin-1 | NP_032412.3 | Mus musculus | v1 | false | false | true | 25 | -67.506 | -55.73892 | -661.741 | -616.11124 | -575.301 | -549.80556 | structures/B4201/S/SPGDLQTLAL.silent | -23.817 | -10.56668 |
HLA-B_42_01 | B*42:01 | B4201 | GPGAGSLQPLAL | 12 | IC50 | 6,066 | nM | purified MHC/competitive/radioactivity | half maximal inhibitory concentration (IC50) | 22,539,795 | Insulin | P01308.1 | Homo sapiens | v1 | false | false | true | 25 | -51.377 | -42.02092 | -641.383 | -570.21532 | -580.154 | -529.11796 | structures/B4201/G/GPGAGSLQPLAL.silent | -10.357 | 0.92372 |
HLA-B_13_02 | B*13:02 | B1302 | ELPKYGVKV | 9 | Kd | 10,000 | nM | purified MHC/direct/fluorescence | dissociation constant (KD) | 34,290,406 | Large ribosomal subunit protein uL18 | A0A2R8Y4A2.1 | Homo sapiens | v1 | false | false | true | 25 | -72.499 | -60.51392 | -656.959 | -602.89072 | -569.14 | -529.86536 | structures/B1302/E/ELPKYGVKV.silent | -23.549 | -12.51156 |
HLA-B_45_01 | B*45:01 | B4501 | SENERGYYI | 9 | IC50 | 336 | nM | purified MHC/competitive/radioactivity | half maximal inhibitory concentration (IC50) | 14,634,108 | Liver stage antigen 1 | Q25893.1 | Plasmodium falciparum | v1 | false | false | true | 25 | -62.648 | -50.77904 | -631.453 | -596.75332 | -563.413 | -541.4912 | structures/B4501/S/SENERGYYI.silent | -13.809 | -4.48308 |
HLA-B_45_01 | B*45:01 | B4501 | RENANQLVV | 9 | IC50 | 37 | nM | purified MHC/competitive/radioactivity | half maximal inhibitory concentration (IC50) | 14,634,108 | Thrombospondin-related anonymous protein | AAG12328.1 | Plasmodium falciparum | v1 | false | false | true | 25 | -70.503 | -63.96212 | -677.671 | -636.52032 | -594.309 | -558.9796 | structures/B4501/R/RENANQLVV.silent | -17.525 | -13.57844 |
HLA-B_45_01 | B*45:01 | B4501 | NELNYDNAGI | 10 | IC50 | 457 | nM | purified MHC/competitive/radioactivity | half maximal inhibitory concentration (IC50) | 14,634,108 | Circumsporozoite protein | AAA29547.1 | Plasmodium falciparum | v1 | false | false | true | 25 | -58.424 | -48.82304 | -656.17 | -603.75768 | -579.154 | -542.04384 | structures/B4501/N/NELNYDNAGI.silent | -24.168 | -12.89088 |
HLA-B_45_01 | B*45:01 | B4501 | AELLAACF | 8 | IC50 | 247 | nM | purified MHC/competitive/radioactivity | half maximal inhibitory concentration (IC50) | 14,634,108 | Protein P | AAP79852.1 | Hepatitis B virus | v1 | false | false | true | 25 | -71.721 | -61.98296 | -656.432 | -617.99328 | -565.646 | -542.5842 | structures/B4501/A/AELLAACF.silent | -19.527 | -13.42612 |
HLA-B_45_01 | B*45:01 | B4501 | AELLAACFA | 9 | IC50 | 6.6 | nM | purified MHC/competitive/radioactivity | half maximal inhibitory concentration (IC50) | 14,634,108 | Protein P | AAP79852.1 | Hepatitis B virus | v1 | false | false | true | 25 | -65.174 | -57.51288 | -667.107 | -625.21276 | -587.657 | -555.0832 | structures/B4501/A/AELLAACFA.silent | -18.539 | -12.61664 |
HLA-B_45_01 | B*45:01 | B4501 | RETVLEYLV | 9 | IC50 | 205 | nM | purified MHC/competitive/radioactivity | half maximal inhibitory concentration (IC50) | 14,634,108 | Capsid protein | AAO62974.1 | Hepatitis B virus | v1 | false | false | true | 25 | -63.272 | -48.9898 | -637.75 | -553.99684 | -570.839 | -500.47804 | structures/B4501/R/RETVLEYLV.silent | -13.146 | -4.52912 |
HLA-B_45_01 | B*45:01 | B4501 | AEAALENLV | 9 | IC50 | 35 | nM | purified MHC/competitive/radioactivity | half maximal inhibitory concentration (IC50) | 14,634,108 | Genome polyprotein | Q81495.3 | Hepatitis C virus (isolate HCV-K3a/650) | v1 | false | false | true | 25 | -65.15 | -60.055 | -654.594 | -639.74668 | -575.513 | -565.83196 | structures/B4501/A/AEAALENLV.silent | -18.549 | -13.85972 |
HLA-B_45_01 | B*45:01 | B4501 | AENLYVTVF | 9 | IC50 | 69 | nM | purified MHC/competitive/radioactivity | half maximal inhibitory concentration (IC50) | 14,634,108 | null | ONTIE_0002602 | Human immunodeficiency virus 1 | v1 | false | false | true | 25 | -70.167 | -54.99372 | -665.551 | -591.5246 | -578.537 | -534.19848 | structures/B4501/A/AENLYVTVF.silent | -17.719 | -2.33232 |
HLA-B_45_01 | B*45:01 | B4501 | AENLWVTVYY | 10 | IC50 | 245 | nM | purified MHC/competitive/radioactivity | half maximal inhibitory concentration (IC50) | 14,634,108 | Envelope glycoprotein gp160 | AAA80623.1 | Human immunodeficiency virus 1 | v1 | false | false | true | 25 | -78.41 | -67.28124 | -688.683 | -630.45048 | -591.664 | -552.83576 | structures/B4501/A/AENLWVTVYY.silent | -21.693 | -10.33356 |
HLA-B_45_01 | B*45:01 | B4501 | AENLWVTVY | 9 | IC50 | 68 | nM | purified MHC/competitive/radioactivity | half maximal inhibitory concentration (IC50) | 14,634,108 | Envelope glycoprotein gp160 | AAA80623.1 | Human immunodeficiency virus 1 | v1 | false | false | true | 25 | -57.953 | -53.35416 | -630.167 | -598.62044 | -559.054 | -533.89752 | structures/B4501/A/AENLWVTVY.silent | -17.758 | -11.36888 |
HLA-B_45_01 | B*45:01 | B4501 | ADKNLIKCS | 9 | IC50 | 70,000 | nM | cellular MHC/competitive/fluorescence | half maximal inhibitory concentration (IC50) | 19,734,234 | RING finger protein Z | AAQ55253.1 | Mammarenavirus guanaritoense | v1 | false | false | true | 25 | -56.235 | -47.85876 | -639.318 | -591.875 | -574.735 | -543.77528 | structures/B4501/A/ADKNLIKCS.silent | -12.817 | -0.24092 |
HLA-B_45_01 | B*45:01 | B4501 | FEFTSFFY | 8 | IC50 | 12,811 | nM | purified MHC/competitive/fluorescence | half maximal inhibitory concentration (IC50) | 18,842,709 | RNA-directed RNA polymerase catalytic subunit | P03431.1 | Influenza A virus | v1 | false | false | true | 25 | -67.987 | -62.85524 | -661.351 | -619.0392 | -575.586 | -541.39884 | structures/B4501/F/FEFTSFFY.silent | -21.48 | -14.78524 |
HLA-B_45_01 | B*45:01 | B4501 | FESKSMKL | 8 | IC50 | 53,678 | nM | purified MHC/competitive/fluorescence | half maximal inhibitory concentration (IC50) | 18,842,709 | RNA-directed RNA polymerase catalytic subunit | P03431.1 | Influenza A virus | v1 | false | false | true | 25 | -62.072 | -57.24244 | -665.447 | -631.56488 | -587.097 | -561.14072 | structures/B4501/F/FESKSMKL.silent | -18.874 | -13.1818 |
HLA-B_45_01 | B*45:01 | B4501 | AEIMKICST | 9 | IC50 | 139 | nM | purified MHC/competitive/radioactivity | half maximal inhibitory concentration (IC50) | 18,842,709 | RNA-directed RNA polymerase catalytic subunit | AAA43637.1 | Influenza A virus | v1 | false | false | true | 25 | -59.037 | -54.54756 | -650.256 | -623.32172 | -577.642 | -556.3718 | structures/B4501/A/AEIMKICST.silent | -16.053 | -12.4022 |
HLA-B_45_01 | B*45:01 | B4501 | AESRKLLLI | 9 | IC50 | 167 | nM | purified MHC/competitive/radioactivity | half maximal inhibitory concentration (IC50) | 18,842,709 | Polymerase acidic protein | NP_775531.1 | Influenza A virus | v1 | false | false | true | 25 | -69.861 | -60.18236 | -651.649 | -609.46284 | -564.908 | -537.65728 | structures/B4501/A/AESRKLLLI.silent | -18.076 | -11.62332 |
HLA-B_45_01 | B*45:01 | B4501 | CEKLEQSGL | 9 | IC50 | 359 | nM | purified MHC/competitive/radioactivity | half maximal inhibitory concentration (IC50) | 18,842,709 | RNA-directed RNA polymerase catalytic subunit | P03431.1 | Influenza A virus | v1 | false | false | true | 25 | -65.581 | -50.93512 | -664.875 | -595.67832 | -582.221 | -533.72588 | structures/B4501/C/CEKLEQSGL.silent | -21.638 | -11.01732 |
HLA-B_45_01 | B*45:01 | B4501 | CELTDSSWI | 9 | IC50 | 139 | nM | purified MHC/competitive/radioactivity | half maximal inhibitory concentration (IC50) | 18,842,709 | Polymerase acidic protein | NP_775531.1 | Influenza A virus | v1 | false | false | true | 25 | -63.875 | -55.97244 | -660.736 | -611.82708 | -580.18 | -542.60468 | structures/B4501/C/CELTDSSWI.silent | -20.024 | -13.25008 |
HLA-B_45_01 | B*45:01 | B4501 | AEIEDLIFLA | 10 | IC50 | 8.9 | nM | purified MHC/competitive/radioactivity | half maximal inhibitory concentration (IC50) | 18,842,709 | Nucleoprotein | AAK18005.1 | Influenza A virus | v1 | false | false | true | 25 | -65.834 | -57.9114 | -637.36 | -596.18384 | -569.83 | -540.26552 | structures/B4501/A/AEIEDLIFLA.silent | -4.638 | 1.99304 |
HLA-B_45_01 | B*45:01 | B4501 | YERMCNILKG | 10 | IC50 | 19,823 | nM | purified MHC/competitive/fluorescence | half maximal inhibitory concentration (IC50) | 18,842,709 | Nucleoprotein | AAK18005.1 | Influenza A virus | v1 | false | false | true | 25 | -71.268 | -57.47764 | -629.788 | -560.96692 | -558.623 | -510.3544 | structures/B4501/Y/YERMCNILKG.silent | 0.103 | 6.865 |
HLA-B_45_01 | B*45:01 | B4501 | AEKPKFLPDLY | 11 | IC50 | 2,929 | nM | purified MHC/competitive/fluorescence | half maximal inhibitory concentration (IC50) | 18,842,709 | Polymerase acidic protein | NP_775531.1 | Influenza A virus | v1 | false | false | true | 25 | -64.325 | -56.31728 | -645.217 | -580.65696 | -564.406 | -515.79184 | structures/B4501/A/AEKPKFLPDLY.silent | -16.486 | -8.54784 |
HLA-B_37_01 | B*37:01 | B3701 | RQSSGSSSSGF | 11 | IC50 | 316.8 | nM | purified MHC/competitive/fluorescence | half maximal inhibitory concentration (IC50) | null | ATP-dependent RNA helicase DDX3Y | NP_004651.2 | Homo sapiens | v1 | false | false | true | 25 | -62.222 | -51.35524 | -668.415 | -607.52448 | -586.431 | -539.79828 | structures/B3701/R/RQSSGSSSSGF.silent | -22.054 | -16.371 |
HLA-B_37_01 | B*37:01 | B3701 | FQILHDRFF | 9 | IC50 | 365.3 | nM | purified MHC/competitive/fluorescence | half maximal inhibitory concentration (IC50) | null | Ubiquitin carboxyl-terminal hydrolase 9Y | EAW91607.1 | Homo sapiens | v1 | false | false | true | 25 | -79.137 | -70.91544 | -679.728 | -597.74116 | -585.791 | -514.53984 | structures/B3701/F/FQILHDRFF.silent | -18.177 | -12.28592 |
HLA-B_37_01 | B*37:01 | B3701 | TEAEKWPFF | 9 | IC50 | 394.2 | nM | purified MHC/competitive/fluorescence | half maximal inhibitory concentration (IC50) | null | Sex-determining region Y protein (Fragment) | ACQ77096.1 | Tarsius lariang | v1 | false | false | true | 25 | -76.132 | -59.043 | -657.891 | -553.40268 | -566.552 | -486.86872 | structures/B3701/T/TEAEKWPFF.silent | -19.825 | -7.49116 |
HLA-B_37_01 | B*37:01 | B3701 | KVADVDLAVPV | 11 | IC50 | 906.6 | nM | purified MHC/competitive/fluorescence | half maximal inhibitory concentration (IC50) | null | Gamma-taxilin | NP_115965.1 | Homo sapiens | v1 | false | false | true | 25 | -72.068 | -48.65932 | -686.789 | -587.24652 | -589.808 | -532.20048 | structures/B3701/K/KVADVDLAVPV.silent | -24.913 | -6.38668 |
HLA-B_37_01 | B*37:01 | B3701 | IVDCLTEMYY | 10 | IC50 | 20,000 | nM | purified MHC/competitive/fluorescence | half maximal inhibitory concentration (IC50) | null | Ubiquitin carboxyl-terminal hydrolase 9Y | EAW91607.1 | Homo sapiens | v1 | false | false | true | 25 | -65.815 | -58.61336 | -645.563 | -591.50192 | -566.793 | -523.2168 | structures/B3701/I/IVDCLTEMYY.silent | -16.826 | -9.67176 |
HLA-B_37_01 | B*37:01 | B3701 | ILNRETLLDFV | 11 | IC50 | 20,000 | nM | purified MHC/competitive/fluorescence | half maximal inhibitory concentration (IC50) | null | Putative gamma-taxilin 2 | AAK13476.1 | Homo sapiens | v1 | false | false | true | 25 | -68.111 | -58.93892 | -653.355 | -585.28032 | -572.504 | -516.44884 | structures/B3701/I/ILNRETLLDFV.silent | -17.735 | -9.89268 |
HLA-B_37_01 | B*37:01 | B3701 | FLLPILSQIYT | 11 | IC50 | 20,000 | nM | purified MHC/competitive/fluorescence | half maximal inhibitory concentration (IC50) | null | RNA helicase | XP_001378186.1 | Monodelphis domestica | v1 | false | false | true | 25 | -77.924 | -66.06712 | -647.486 | -577.18072 | -564.344 | -512.06672 | structures/B3701/F/FLLPILSQIYT.silent | -9.442 | 0.953 |
HLA-B_37_01 | B*37:01 | B3701 | SLMASSPTSI | 10 | IC50 | 20,000 | nM | purified MHC/competitive/fluorescence | half maximal inhibitory concentration (IC50) | null | Lysine-specific demethylase 5D | AAC50806.1 | Homo sapiens | v1 | false | false | true | 25 | -62.566 | -52.085 | -666.767 | -612.32792 | -582.304 | -545.1512 | structures/B3701/S/SLMASSPTSI.silent | -22.693 | -15.09176 |
HLA-B_37_01 | B*37:01 | B3701 | SLLERGQQLGV | 11 | IC50 | 20,000 | nM | purified MHC/competitive/fluorescence | half maximal inhibitory concentration (IC50) | null | [histone H3]-trimethyl-L-lysine(4) demethylase | XP_001064297.1 | Rattus norvegicus | v1 | false | false | true | 25 | -62.91 | -54.9784 | -666.785 | -602.51272 | -588.544 | -537.38936 | structures/B3701/S/SLLERGQQLGV.silent | -21.091 | -10.14492 |
HLA-B_37_01 | B*37:01 | B3701 | MIKYCLLKILK | 11 | IC50 | 20,000 | nM | purified MHC/competitive/fluorescence | half maximal inhibitory concentration (IC50) | null | Histone demethylase UTY | NP_033510.2 | Mus musculus | v1 | false | false | true | 25 | -72.8 | -62.67136 | -663.327 | -613.46608 | -581.791 | -539.77944 | structures/B3701/M/MIKYCLLKILK.silent | -17.774 | -11.01548 |
HLA-B_37_01 | B*37:01 | B3701 | GSSDFQVHFLK | 11 | IC50 | 20,000 | nM | purified MHC/competitive/fluorescence | half maximal inhibitory concentration (IC50) | null | Ubiquitin carboxyl-terminal hydrolase 9Y | EAW91607.1 | Homo sapiens | v1 | false | false | true | 25 | -57.575 | -51.12988 | -612.849 | -577.37816 | -556.552 | -532.73052 | structures/B3701/G/GSSDFQVHFLK.silent | 0.234 | 6.48224 |
HLA-B_37_01 | B*37:01 | B3701 | YSLEYFQFVKK | 11 | IC50 | 20,000 | nM | purified MHC/competitive/fluorescence | half maximal inhibitory concentration (IC50) | null | ubiquitinyl hydrolase 1 | XP_001366553.1 | Monodelphis domestica | v1 | false | false | true | 25 | -55.55 | -43.78076 | -629.132 | -534.21948 | -563.228 | -483.16448 | structures/B3701/Y/YSLEYFQFVKK.silent | -19.476 | -7.27456 |
HLA-B_37_01 | B*37:01 | B3701 | KSLTTTMQFK | 10 | IC50 | 20,000 | nM | purified MHC/competitive/fluorescence | half maximal inhibitory concentration (IC50) | null | Protocadherin-11 Y-linked | NP_116753.1 | Homo sapiens | v1 | false | false | true | 25 | -68.65 | -55.95528 | -657.886 | -547.51672 | -581.743 | -487.25688 | structures/B3701/K/KSLTTTMQFK.silent | -15.204 | -4.3046 |
HLA-B_37_01 | B*37:01 | B3701 | SYMMDDLELI | 10 | IC50 | 20,000 | nM | purified MHC/competitive/fluorescence | half maximal inhibitory concentration (IC50) | null | Ubiquitin carboxyl-terminal hydrolase 9Y | EAW91607.1 | Homo sapiens | v1 | false | false | true | 25 | -65.175 | -45.80056 | -599.518 | -537.91676 | -545.016 | -493.8796 | structures/B3701/S/SYMMDDLELI.silent | -7.825 | 1.76344 |
HLA-B_37_01 | B*37:01 | B3701 | YFYYNAFHWAI | 11 | IC50 | 20,000 | nM | purified MHC/competitive/fluorescence | half maximal inhibitory concentration (IC50) | null | Histone demethylase UTY | AAY16579.1 | Homo sapiens | v1 | false | false | true | 25 | -75.114 | -47.96064 | -672.31 | -529.69892 | -581.115 | -486.819 | structures/B3701/Y/YFYYNAFHWAI.silent | -19.053 | 5.08068 |
HLA-B_37_01 | B*37:01 | B3701 | RYSHWTKL | 8 | IC50 | 20,000 | nM | purified MHC/competitive/fluorescence | half maximal inhibitory concentration (IC50) | null | Sex-determining region Y protein | P48046.1 | Gorilla gorilla gorilla | v1 | false | false | true | 25 | -71.413 | -64.78216 | -671.131 | -635.7202 | -576.454 | -553.77656 | structures/B3701/R/RYSHWTKL.silent | -23.264 | -17.16152 |
HLA-B_37_01 | B*37:01 | B3701 | SSKMFNYFK | 9 | IC50 | 20,000 | nM | purified MHC/competitive/fluorescence | half maximal inhibitory concentration (IC50) | null | Isoform 4 of Neuroligin-4, Y-linked | AAH32567.1 | Homo sapiens | v1 | false | false | true | 25 | -68.671 | -60.5686 | -680.193 | -646.37164 | -592.726 | -570.51288 | structures/B3701/S/SSKMFNYFK.silent | -19.165 | -15.29024 |
HLA-B_37_01 | B*37:01 | B3701 | RMILPMSRAFR | 11 | IC50 | 20,000 | nM | purified MHC/competitive/fluorescence | half maximal inhibitory concentration (IC50) | null | Ubiquitin carboxyl-terminal hydrolase 9Y | NP_683745.2 | Mus musculus | v1 | false | false | true | 25 | -70.444 | -59.84712 | -671.17 | -620.41292 | -588.983 | -552.69332 | structures/B3701/R/RMILPMSRAFR.silent | -17.744 | -7.8724 |
HLA-B_37_01 | B*37:01 | B3701 | ELFARSSDPR | 10 | IC50 | 20,000 | nM | purified MHC/competitive/fluorescence | half maximal inhibitory concentration (IC50) | null | Ubiquitin carboxyl-terminal hydrolase 9Y | EAW91607.1 | Homo sapiens | v1 | false | false | true | 25 | -62.931 | -55.01676 | -660.785 | -622.36884 | -580.406 | -557.77332 | structures/B3701/E/ELFARSSDPR.silent | -21.067 | -9.5788 |
HLA-B_37_01 | B*37:01 | B3701 | LVTMGTGTFGR | 11 | IC50 | 20,000 | nM | purified MHC/competitive/fluorescence | half maximal inhibitory concentration (IC50) | null | Putative serine/threonine-protein kinase PRKY | O43930.1 | Homo sapiens | v1 | false | false | true | 25 | -53.97 | -44.43336 | -600.562 | -563.80792 | -548.624 | -522.7722 | structures/B3701/L/LVTMGTGTFGR.silent | -5.196 | 3.3976 |
HLA-B_37_01 | B*37:01 | B3701 | LPADPASVL | 9 | IC50 | 20,000 | nM | purified MHC/competitive/fluorescence | half maximal inhibitory concentration (IC50) | null | Sex-determining region Y protein (Fragment) | ABM65922.1 | Ateles geoffroyi | v1 | false | false | true | 25 | -69.752 | -63.64756 | -692.045 | -661.10712 | -594.867 | -574.02864 | structures/B3701/L/LPADPASVL.silent | -28.151 | -23.43076 |
HLA-B_37_01 | B*37:01 | B3701 | MVRVLTVIKEY | 11 | IC50 | 20,000 | nM | purified MHC/competitive/fluorescence | half maximal inhibitory concentration (IC50) | null | Ubiquitin carboxyl-terminal hydrolase 9Y | CAA73940.1 | Homo sapiens | v1 | false | false | true | 25 | -64.674 | -55.45652 | -615.495 | -565.0086 | -545.741 | -506.33868 | structures/B3701/M/MVRVLTVIKEY.silent | -12.603 | -3.21352 |
HLA-B_37_01 | B*37:01 | B3701 | YQSMIRPPY | 9 | IC50 | 20,000 | nM | purified MHC/competitive/fluorescence | half maximal inhibitory concentration (IC50) | null | Amelogenin, Y isoform (Fragment) | XP_001145496.1 | Pan troglodytes | v1 | false | false | true | 25 | -62.939 | -50.04824 | -623.539 | -574.887 | -561.749 | -525.18168 | structures/B3701/Y/YQSMIRPPY.silent | -7.841 | 0.34272 |
HLA-B_37_01 | B*37:01 | B3701 | VALFSSCPVAY | 11 | IC50 | 20,000 | nM | purified MHC/competitive/fluorescence | half maximal inhibitory concentration (IC50) | null | Ubiquitin carboxyl-terminal hydrolase 9X | NP_033507.2 | Mus musculus | v1 | false | false | true | 25 | -71.586 | -50.88532 | -556.58 | -458.43712 | -525.542 | -459.35456 | structures/B3701/V/VALFSSCPVAY.silent | 36.347 | 51.803 |
HLA-B_37_01 | B*37:01 | B3701 | FPHTELANL | 9 | IC50 | 20,000 | nM | purified MHC/competitive/fluorescence | half maximal inhibitory concentration (IC50) | null | Ubiquitin carboxyl-terminal hydrolase 9Y | EAW91607.1 | Homo sapiens | v1 | false | false | true | 25 | -72.132 | -57.74936 | -670.724 | -556.48016 | -579.509 | -486.60604 | structures/B3701/F/FPHTELANL.silent | -22.573 | -12.12484 |
HLA-B_37_01 | B*37:01 | B3701 | LPSCPTNFCIF | 11 | IC50 | 20,000 | nM | purified MHC/competitive/fluorescence | half maximal inhibitory concentration (IC50) | null | Isoform 2 of Histone demethylase UTY | BAF85547.1 | Homo sapiens | v1 | false | false | true | 25 | -66.455 | -45.78624 | -643.458 | -534.22504 | -572.898 | -488.46552 | structures/B3701/L/LPSCPTNFCIF.silent | -16.345 | 0.02668 |
HLA-B_37_01 | B*37:01 | B3701 | RPPYSSYGY | 9 | IC50 | 20,000 | nM | purified MHC/competitive/fluorescence | half maximal inhibitory concentration (IC50) | null | Amelogenin, Y isoform (Fragment) | XP_001145496.1 | Pan troglodytes | v1 | false | false | true | 25 | -60.95 | -54.448 | -655.552 | -573.24972 | -578.224 | -500.91216 | structures/B3701/R/RPPYSSYGY.silent | -22.526 | -17.8896 |
HLA-B_37_01 | B*37:01 | B3701 | TFVPIAWAAAY | 11 | IC50 | 20,000 | nM | purified MHC/competitive/fluorescence | half maximal inhibitory concentration (IC50) | null | Zinc finger protein Y-linked | ACL51661.1 | Callithrix jacchus | v1 | false | false | true | 25 | -71.466 | -60.43368 | -640.65 | -577.1496 | -558.722 | -516.98236 | structures/B3701/T/TFVPIAWAAAY.silent | -10.871 | 0.2666 |
HLA-B_37_01 | B*37:01 | B3701 | LEYFQFVKKLL | 11 | IC50 | 20,000 | nM | purified MHC/competitive/fluorescence | half maximal inhibitory concentration (IC50) | null | ubiquitinyl hydrolase 1 | XP_001366553.1 | Monodelphis domestica | v1 | false | false | true | 25 | -69.929 | -59.62724 | -608.538 | -559.42856 | -539.473 | -494.05988 | structures/B3701/L/LEYFQFVKKLL.silent | -19.059 | -5.74156 |
HLA-B_37_01 | B*37:01 | B3701 | YPDPVIKV | 8 | IC50 | 20,000 | nM | purified MHC/competitive/fluorescence | half maximal inhibitory concentration (IC50) | null | Small ribosomal subunit protein eS4, Y isoform 1 | EAX02770.1 | Homo sapiens | v1 | false | false | true | 25 | -69.057 | -61.93628 | -697.151 | -657.31248 | -606.838 | -577.70532 | structures/B3701/Y/YPDPVIKV.silent | -23.108 | -17.67068 |
HLA-B_52_01 | B*52:01 | B5201 | QGFPWDILF | 9 | IC50 | 18 | nM | purified MHC/competitive/radioactivity | half maximal inhibitory concentration (IC50) | 30,664,876 | Large delta antigen | AAG26087.1 | Hepatitis delta virus | v1 | false | false | true | 25 | -74.48 | -63.53208 | -633.446 | -583.69456 | -548.735 | -509.63252 | structures/B5201/Q/QGFPWDILF.silent | -20.102 | -10.52996 |
HLA-B_52_01 | B*52:01 | B5201 | DRGFPWDILF | 10 | IC50 | 4,682 | nM | purified MHC/competitive/radioactivity | half maximal inhibitory concentration (IC50) | 30,664,876 | Large delta antigen | AVV65245.1 | Hepatitis delta virus | v1 | false | false | true | 25 | -71.845 | -60.40792 | -631.154 | -573.16772 | -547.616 | -503.21284 | structures/B5201/D/DRGFPWDILF.silent | -19.067 | -9.547 |
HLA-B_52_01 | B*52:01 | B5201 | NQGIPWDILF | 10 | IC50 | 1,469 | nM | purified MHC/competitive/radioactivity | half maximal inhibitory concentration (IC50) | 30,664,876 | Large delta antigen | ONTIE_0003412 | Hepatitis delta virus | v1 | false | false | true | 25 | -76.341 | -64.2522 | -648.453 | -577.42328 | -552.953 | -497.4428 | structures/B5201/N/NQGIPWDILF.silent | -25.429 | -15.72844 |
HLA-B_52_01 | B*52:01 | B5201 | QGFPWDMLF | 9 | IC50 | 90 | nM | purified MHC/competitive/radioactivity | half maximal inhibitory concentration (IC50) | 30,664,876 | Large delta antigen | AAF13849.1 | Hepatitis delta virus | v1 | false | false | true | 25 | -74.167 | -62.51856 | -654.384 | -608.148 | -565.182 | -532.5892 | structures/B5201/Q/QGFPWDMLF.silent | -20.824 | -13.04024 |
HLA-B_52_01 | B*52:01 | B5201 | RGFPWDILF | 9 | IC50 | 224 | nM | purified MHC/competitive/radioactivity | half maximal inhibitory concentration (IC50) | 30,664,876 | Large delta antigen | AVV65245.1 | Hepatitis delta virus | v1 | false | false | true | 25 | -82.872 | -70.26964 | -669.828 | -624.97324 | -577.686 | -542.45188 | structures/B5201/R/RGFPWDILF.silent | -18.435 | -12.25152 |
HLA-B_52_01 | B*52:01 | B5201 | QGFPWDLLF | 9 | IC50 | 135 | nM | purified MHC/competitive/radioactivity | half maximal inhibitory concentration (IC50) | 30,664,876 | Large delta antigen | AAO49188.1 | Hepatitis delta virus | v1 | false | false | true | 25 | -71.632 | -62.08712 | -644.596 | -587.04708 | -557.888 | -513.72808 | structures/B5201/Q/QGFPWDLLF.silent | -20.042 | -11.23188 |
HLA-B_52_01 | B*52:01 | B5201 | SQGFPWDILF | 10 | IC50 | 3,657 | nM | purified MHC/competitive/radioactivity | half maximal inhibitory concentration (IC50) | 30,664,876 | Large delta antigen | P25989.1 | Hepatitis delta virus | v1 | false | false | true | 25 | -70.485 | -59.513 | -634.22 | -570.5102 | -546.067 | -498.17188 | structures/B5201/S/SQGFPWDILF.silent | -22.32 | -12.82552 |
HLA-B_14_02 | B*14:02 | B1402 | MVFGRFSFA | 9 | Kd | 1,178 | nM | purified MHC/direct/fluorescence | dissociation constant (KD) | null | Membrane protein, putative | AAU48420.1 | Burkholderia mallei ATCC 23344 | v1 | false | false | true | 25 | -69.311 | -57.9836 | -648.499 | -606.91628 | -566.687 | -541.4444 | structures/B1402/M/MVFGRFSFA.silent | -16.513 | -7.48844 |
HLA-B_14_02 | B*14:02 | B1402 | FRKAQIQGL | 9 | Kd | 3,000 | nM | purified MHC/competitive/fluorescence | dissociation constant (KD) | null | Epstein-Barr nuclear antigen 6 | S33015 | human gammaherpesvirus 4 | v1 | false | false | true | 25 | -75.715 | -61.94064 | -622.512 | -582.84792 | -556.98 | -532.47756 | structures/B1402/F/FRKAQIQGL.silent | 3.021 | 11.5702 |
HLA-B_14_02 | B*14:02 | B1402 | TGIAIIAYI | 9 | Kd | 5,000 | nM | purified MHC/competitive/fluorescence | dissociation constant (KD) | null | Lmo2486 protein | CAD00564.1 | Listeria monocytogenes EGD-e | v1 | false | false | true | 25 | -59.166 | -53.26332 | -645.345 | -621.61384 | -570.578 | -557.00676 | structures/B1402/T/TGIAIIAYI.silent | -16.242 | -11.34372 |
HLA-B_14_02 | B*14:02 | B1402 | YLDNVGVHI | 9 | Kd | 5,000 | nM | purified MHC/competitive/fluorescence | dissociation constant (KD) | null | Phosphoprotein | AAK55078.1 | Lyssavirus rabies | v1 | false | false | true | 25 | -67.148 | -55.31436 | -682.108 | -595.16484 | -593.277 | -532.3088 | structures/B1402/Y/YLDNVGVHI.silent | -21.683 | -7.5416 |
HLA-B_14_02 | B*14:02 | B1402 | TRAPAPFPL | 9 | Kd | 565 | nM | purified MHC/competitive/fluorescence | dissociation constant (KD) | null | DNA polymerase III subunit epsilon | AAL59738.1 | Vibrio cholerae | v1 | false | false | true | 25 | -67.844 | -62.19412 | -679.848 | -627.71972 | -586.426 | -542.31012 | structures/B1402/T/TRAPAPFPL.silent | -29.476 | -23.21556 |
HLA-B_14_02 | B*14:02 | B1402 | TTRAVNMEV | 9 | Kd | 5,000 | nM | purified MHC/competitive/fluorescence | dissociation constant (KD) | null | Gluconate 2-dehydrogenase | AAL53555.1 | Brucella melitensis bv. 1 str. 16M | v1 | false | false | true | 25 | -66.709 | -58.7138 | -635.707 | -611.0774 | -559.67 | -539.51176 | structures/B1402/T/TTRAVNMEV.silent | -17.915 | -12.85168 |
HLA-B_14_02 | B*14:02 | B1402 | KQIVIINPM | 9 | Kd | 5,000 | nM | purified MHC/competitive/fluorescence | dissociation constant (KD) | null | GlcNAc phosphomutase | AAO10081.1 | Vibrio vulnificus CMCP6 | v1 | false | false | true | 25 | -67.479 | -58.4312 | -688.231 | -632.54028 | -597.603 | -559.2902 | structures/B1402/K/KQIVIINPM.silent | -24.859 | -14.81884 |
HLA-B_14_02 | B*14:02 | B1402 | MYPFIFFIV | 9 | Kd | 5,000 | nM | purified MHC/competitive/fluorescence | dissociation constant (KD) | null | Hypothetical membrane spanning protein | AAO90371.1 | Coxiella burnetii RSA 493 | v1 | false | false | true | 25 | -73.881 | -62.122 | -663.03 | -582.06456 | -577.271 | -510.70292 | structures/B1402/M/MYPFIFFIV.silent | -19.423 | -9.23968 |
HLA-B_14_02 | B*14:02 | B1402 | WAIQCYTGV | 9 | Kd | 5,000 | nM | purified MHC/competitive/fluorescence | dissociation constant (KD) | null | Na+/H+ antiporter NhaC | AAO07968.1 | Vibrio vulnificus CMCP6 | v1 | false | false | true | 25 | -65.231 | -57.37472 | -645.435 | -594.9872 | -566.022 | -530.05536 | structures/B1402/W/WAIQCYTGV.silent | -15.205 | -7.55728 |
HLA-B_14_02 | B*14:02 | B1402 | ELAPIRVNA | 9 | Kd | 5,000 | nM | purified MHC/competitive/fluorescence | dissociation constant (KD) | null | Dehydrogenases with different specificities | BAC97625.1 | Vibrio vulnificus YJ016 | v1 | false | false | true | 25 | -61.822 | -46.2502 | -670.9 | -560.5836 | -592.077 | -507.61656 | structures/B1402/E/ELAPIRVNA.silent | -21.283 | -6.7168 |
HLA-B_14_02 | B*14:02 | B1402 | FTWQHNYYL | 9 | Kd | 20,000 | nM | purified MHC/competitive/fluorescence | dissociation constant (KD) | null | 40S ribosomal protein S10 | EAK87991.1 | Cryptosporidium parvum Iowa II | v1 | false | false | true | 25 | -80.731 | -70.75696 | -687.794 | -623.66684 | -585.847 | -542.85092 | structures/B1402/F/FTWQHNYYL.silent | -21.216 | -10.05904 |
HLA-B_14_02 | B*14:02 | B1402 | NGNFNFERV | 9 | Kd | 5,000 | nM | purified MHC/competitive/fluorescence | dissociation constant (KD) | null | Glucosidase II subunit alpha | EAK89133.1 | Cryptosporidium parvum Iowa II | v1 | false | false | true | 25 | -70.121 | -59.77908 | -631.297 | -593.594 | -550.607 | -524.95192 | structures/B1402/N/NGNFNFERV.silent | -12.706 | -8.863 |
HLA-B_14_02 | B*14:02 | B1402 | SVFELSNFA | 9 | Kd | 5,000 | nM | purified MHC/competitive/fluorescence | dissociation constant (KD) | null | null | BAC93293.1 | Vibrio vulnificus YJ016 | v1 | false | false | true | 25 | -64.036 | -53.24384 | -637.085 | -561.54484 | -567.053 | -502.47372 | structures/B1402/S/SVFELSNFA.silent | -16.945 | -5.82728 |
HLA-B_14_02 | B*14:02 | B1402 | TVFRNQNRV | 9 | Kd | 5,000 | nM | purified MHC/competitive/fluorescence | dissociation constant (KD) | null | Shares a domain with a conserved HREF motif with the CWF15 protein that is involved in mRNA splicing | EAK89397.1 | Cryptosporidium parvum Iowa II | v1 | false | false | true | 25 | -70.937 | -52.80768 | -656.563 | -422.71072 | -572.836 | -367.55036 | structures/B1402/T/TVFRNQNRV.silent | -16.253 | -2.35284 |
HLA-B_14_02 | B*14:02 | B1402 | ERAFQNWSV | 9 | Kd | 5,000 | nM | purified MHC/competitive/fluorescence | dissociation constant (KD) | null | DNA topoisomerase | EAL47247.1 | Entamoeba histolytica HM-1:IMSS | v1 | false | false | true | 25 | -66.12 | -52.12504 | -666.357 | -572.55844 | -577.903 | -513.3426 | structures/B1402/E/ERAFQNWSV.silent | -22.334 | -7.0908 |
HLA-B_14_02 | B*14:02 | B1402 | FTLINWRSV | 9 | Kd | 5,000 | nM | purified MHC/competitive/fluorescence | dissociation constant (KD) | null | tRNA pseudouridine synthase, putative | EAL50898.1 | Entamoeba histolytica HM-1:IMSS | v1 | false | false | true | 25 | -76.43 | -64.943 | -683.582 | -627.44972 | -585.182 | -550.28072 | structures/B1402/F/FTLINWRSV.silent | -21.971 | -12.22592 |
HLA-B_14_02 | B*14:02 | B1402 | IESNPLFPV | 9 | Kd | 5,000 | nM | purified MHC/competitive/fluorescence | dissociation constant (KD) | null | Dedicator of cytokinesis protein | EAL49146.1 | Entamoeba histolytica HM-1:IMSS | v1 | false | false | true | 25 | -63.457 | -57.03852 | -668.703 | -624.90664 | -581.624 | -549.94452 | structures/B1402/I/IESNPLFPV.silent | -25.251 | -17.9234 |
HLA-B_14_02 | B*14:02 | B1402 | NPAACSYMV | 9 | Kd | 5,000 | nM | purified MHC/competitive/fluorescence | dissociation constant (KD) | null | Uncharacterized protein | EAL50926.1 | Entamoeba histolytica HM-1:IMSS | v1 | false | false | true | 25 | -58.039 | -51.36324 | -643.159 | -497.57752 | -572.187 | -437.90416 | structures/B1402/N/NPAACSYMV.silent | -17.466 | -8.30996 |
HLA-B_14_02 | B*14:02 | B1402 | EGAGIDDPV | 9 | Kd | 5,000 | nM | purified MHC/competitive/fluorescence | dissociation constant (KD) | null | AcrB/AcrD/AcrF family protein | EAL56425.1 | Campylobacter coli RM2228 | v1 | false | false | true | 25 | -56.493 | -49.61688 | -645.272 | -610.59972 | -578.348 | -551.3372 | structures/B1402/E/EGAGIDDPV.silent | -14.761 | -9.6456 |
HLA-B_14_02 | B*14:02 | B1402 | FFSPFFFSL | 9 | Kd | 5,000 | nM | purified MHC/competitive/fluorescence | dissociation constant (KD) | null | Clustered-asparagine-rich protein | CAJ20722.1 | Toxoplasma gondii RH | v1 | false | false | true | 25 | -72.649 | -61.55448 | -652.901 | -552.45 | -569.981 | -487.23292 | structures/B1402/F/FFSPFFFSL.silent | -13.774 | -3.66264 |
HLA-B_14_02 | B*14:02 | B1402 | FMVYVPLPA | 9 | Kd | 5,000 | nM | purified MHC/competitive/fluorescence | dissociation constant (KD) | null | Isocitrate dehydrogenase kinase/phosphatase | ABG16349.1 | Yersinia pestis Nepal516 | v1 | false | false | true | 25 | -74.6 | -64.32392 | -695.44 | -618.02012 | -600.191 | -540.19664 | structures/B1402/F/FMVYVPLPA.silent | -22.398 | -13.49964 |
HLA-B_14_02 | B*14:02 | B1402 | YQAENSTAE | 9 | Kd | 5,000 | nM | purified MHC/competitive/fluorescence | dissociation constant (KD) | null | Protein bdm | ABG69490.1 | Escherichia coli 536 | v1 | false | false | true | 25 | -63.58 | -52.1062 | -659.524 | -563.92868 | -581.016 | -498.88632 | structures/B1402/Y/YQAENSTAE.silent | -21.418 | -12.93608 |
HLA-B_14_02 | B*14:02 | B1402 | FGALFMWLL | 9 | Kd | 5,000 | nM | purified MHC/competitive/fluorescence | dissociation constant (KD) | null | Cytochrome oxidase subunit | ABF04835.1 | Shigella flexneri 5 str. 8401 | v1 | false | false | true | 25 | -82.326 | -76.42628 | -688.122 | -664.48168 | -584.931 | -567.92088 | structures/B1402/F/FGALFMWLL.silent | -23.582 | -20.1346 |
HLA-B_14_02 | B*14:02 | B1402 | KQIGGTLFE | 9 | Kd | 5,000 | nM | purified MHC/competitive/fluorescence | dissociation constant (KD) | null | Glutamate 5-kinase | CAL34268.1 | Campylobacter jejuni subsp. jejuni NCTC 11168 = ATCC 700819 | v1 | false | false | true | 25 | -61.115 | -51.3944 | -642.62 | -529.70212 | -573.427 | -473.67064 | structures/B1402/K/KQIGGTLFE.silent | -15.717 | -4.63724 |
HLA-B_14_02 | B*14:02 | B1402 | QQRPDLILV | 9 | Kd | 5,000 | nM | purified MHC/competitive/fluorescence | dissociation constant (KD) | null | Endonuclease V | CAL22320.1 | Yersinia pestis CO92 | v1 | false | false | true | 25 | -54.798 | -33.762 | -595.538 | -493.959 | -543.51 | -471.84996 | structures/B1402/Q/QQRPDLILV.silent | -6.37 | 11.65304 |
HLA-B_14_02 | B*14:02 | B1402 | GVDGGWQAL | 9 | Kd | 5,000 | nM | purified MHC/competitive/fluorescence | dissociation constant (KD) | null | UDP-N-acetylmuramate--L-alanyl-gamma-D-glutamyl-meso-2,6-diaminoheptandioate ligase | ABM49996.1 | Burkholderia mallei SAVP1 | v1 | false | false | true | 25 | -61.466 | -54.89272 | -637.768 | -593.86744 | -569.032 | -530.25024 | structures/B1402/G/GVDGGWQAL.silent | -12.054 | -8.72456 |
HLA-B_14_02 | B*14:02 | B1402 | MGMEQTMSV | 9 | Kd | 5,000 | nM | purified MHC/competitive/fluorescence | dissociation constant (KD) | null | MSHA biogenesis protein MshN | EAX58236.1 | Vibrio cholerae 2740-80 | v1 | false | false | true | 25 | -73.639 | -61.67812 | -659.908 | -611.37396 | -570.395 | -536.4926 | structures/B1402/M/MGMEQTMSV.silent | -20.886 | -13.20332 |
HLA-B_14_02 | B*14:02 | B1402 | NVMDPMHGA | 9 | Kd | 5,000 | nM | purified MHC/competitive/fluorescence | dissociation constant (KD) | null | Iron-sulfur cluster-binding protein, rieske family | ABM49342.1 | Burkholderia mallei SAVP1 | v1 | false | false | true | 25 | -73.086 | -64.3278 | -693.06 | -639.89916 | -600.678 | -556.51204 | structures/B1402/N/NVMDPMHGA.silent | -23.624 | -19.05924 |
HLA-B_14_02 | B*14:02 | B1402 | RVACRDVEV | 9 | Kd | 3,000 | nM | purified MHC/competitive/fluorescence | dissociation constant (KD) | null | Putative cytochrome P450 140 | CAL71904.1 | Mycobacterium tuberculosis variant bovis BCG str. Pasteur 1173P2 | v1 | false | false | true | 25 | -60.661 | -51.07828 | -646.182 | -586.4138 | -577.677 | -528.16448 | structures/B1402/R/RVACRDVEV.silent | -13.243 | -7.17104 |
HLA-B_14_02 | B*14:02 | B1402 | EGFDPRALI | 9 | Kd | 5,000 | nM | purified MHC/competitive/fluorescence | dissociation constant (KD) | null | Glycerophosphoryl diester phosphodiesterase family protein | ABQ60400.1 | Brucella ovis ATCC 25840 | v1 | false | false | true | 25 | -61.735 | -48.36064 | -621.213 | -522.0844 | -562.366 | -481.73144 | structures/B1402/E/EGFDPRALI.silent | -5.346 | 8.00776 |
HLA-B_14_02 | B*14:02 | B1402 | HQFTSNPEV | 9 | Kd | 5,000 | nM | purified MHC/competitive/fluorescence | dissociation constant (KD) | null | FHA domain-containing protein | EDM60245.1 | Vibrio parahaemolyticus AQ3810 | v1 | false | false | true | 25 | -73.445 | -67.16672 | -693.396 | -635.72204 | -598.857 | -546.5586 | structures/B1402/H/HQFTSNPEV.silent | -26.585 | -21.99684 |
HLA-B_14_02 | B*14:02 | B1402 | MTACGRIVV | 9 | Kd | 5,000 | nM | purified MHC/competitive/fluorescence | dissociation constant (KD) | null | TfuA-like core domain-containing protein | EBA41824.1 | Mycobacterium tuberculosis str. Haarlem | v1 | false | false | true | 25 | -69.854 | -63.823 | -655.147 | -586.6378 | -574.499 | -513.52472 | structures/B1402/M/MTACGRIVV.silent | -14.409 | -9.29 |
HLA-B_14_02 | B*14:02 | B1402 | EDFEIFYNL | 9 | Kd | 5,000 | nM | purified MHC/competitive/fluorescence | dissociation constant (KD) | null | Ribonuclease D | ABV79247.1 | Rickettsia bellii OSU 85-389 | v1 | false | false | true | 25 | -71.851 | -62.69236 | -685.804 | -626.39016 | -590.307 | -547.11644 | structures/B1402/E/EDFEIFYNL.silent | -24.616 | -16.58136 |
HLA-B_14_02 | B*14:02 | B1402 | ETVWPFFYA | 9 | Kd | 5,000 | nM | purified MHC/competitive/fluorescence | dissociation constant (KD) | null | Nitrate reductase | ABX61793.1 | Brucella canis ATCC 23365 | v1 | false | false | true | 25 | -65.901 | -59.58956 | -636.175 | -605.00608 | -567.653 | -544.34656 | structures/B1402/E/ETVWPFFYA.silent | -7.541 | -1.06996 |
HLA-B_14_02 | B*14:02 | B1402 | FTARIIIFS | 9 | Kd | 5,000 | nM | purified MHC/competitive/fluorescence | dissociation constant (KD) | null | Uncharacterized protein | ABV75419.1 | Rickettsia akari str. Hartford | v1 | false | false | true | 25 | -75.337 | -66.58332 | -670.124 | -575.94348 | -575.874 | -493.35328 | structures/B1402/F/FTARIIIFS.silent | -21.05 | -16.0068 |
HLA-B_14_02 | B*14:02 | B1402 | FVMPIFEQI | 9 | Kd | 5,000 | nM | purified MHC/competitive/fluorescence | dissociation constant (KD) | null | Prophage LambdaBa01, membrane protein | EDR16741.1 | Bacillus anthracis str. A0488 | v1 | false | false | true | 25 | -81.906 | -72.99944 | -685.454 | -649.78848 | -583.321 | -560.90872 | structures/B1402/F/FVMPIFEQI.silent | -22.337 | -15.8804 |
HLA-B_14_02 | B*14:02 | B1402 | MTFPLHFRS | 9 | Kd | 5,000 | nM | purified MHC/competitive/fluorescence | dissociation constant (KD) | null | Uncharacterized protein | EDO77069.1 | Giardia lamblia ATCC 50803 | v1 | false | false | true | 25 | -68.042 | -62.02836 | -681.225 | -639.79876 | -595.791 | -562.99972 | structures/B1402/M/MTFPLHFRS.silent | -21.079 | -14.77076 |
HLA-B_14_02 | B*14:02 | B1402 | MTYLDGHPV | 9 | Kd | 5,000 | nM | purified MHC/competitive/fluorescence | dissociation constant (KD) | null | Uncharacterized protein | EDO78551.1 | Giardia lamblia ATCC 50803 | v1 | false | false | true | 25 | -76.937 | -69.27808 | -704.778 | -663.0394 | -599.185 | -572.5628 | structures/B1402/M/MTYLDGHPV.silent | -30.118 | -21.19864 |
PepBind3D
Curated peptide-HLA class I binding affinities paired with Rosetta FlexPepDock structural ensembles. 112,561 peptide-allele pairs across 95 HLA-A, -B and -C alleles, each with 25 docked decoy structures and per-decoy interface energies.
Authors: Kuniko Hunter, Rocco Moretti, Jens Meiler, David G. Harrison
Produced at: Vanderbilt University / Vanderbilt University Medical Center
License: CC BY 4.0
Metadata source: Immune Epitope Database (IEDB)
Dataset Summary
The interaction between peptide antigens and class I human leukocyte antigens (HLA) is a central determinant of CD8βΊ T cell recognition, and a foundational target for cancer immunotherapy, vaccine design and autoimmune disease research. Computational prediction of peptide-HLA (pHLA) binding has progressed rapidly with sequence-based machine learning, but structure-aware approaches remain limited by the scarcity of paired experimental affinity data and three-dimensional structural information.
This dataset pairs the two: every peptide-allele pair carries an experimental binding measurement and an ensemble of 25 Rosetta FlexPepDock decoys with their energy terms. Each pair gives a distribution over peptide conformations rather than a single pose. Pairs measured by both IC50 and Kd appear as separate rows, giving 118,985 rows over 112,561 pairs.
Intended uses:
- Training and benchmarking machine learning models for pHLA binding affinity prediction, particularly models that consume explicit structural features
- Evaluating computational docking and scoring methods against experimental binding data
- Downstream structural analysis: anchor residue mapping, conformational diversity, interface comparison between binders and non-binders
Dataset Statistics
| Metric | Count |
|---|---|
| Peptide-allele pairs (silent files) | 112,561 |
| Total measurements (metadata rows) | 118,985 |
| Unique alleles | 95 (HLA-A, -B, -C) |
| Unique peptides | 25,622 |
| Peptide lengths | 7-15 residues |
| IC50 measurements | 21,234 |
| Kd measurements | 97,751 |
| Censored measurements | 52,462 (44%) |
| Flagged entries | 15 |
| Self-templated pairs | 370 (0.33%) |
| Total decoy structures | 2,814,025 |
| Approximate size | ~155 GB |
Dataset Structure
PepBind3D/
βββ README.md
βββ metadata.csv # Master table - one row per IEDB measurement
βββ structures/
βββ A0101/
β βββ F/
β β βββ FHEFLSSKL.silent
β βββ G/
β β βββ GILGFVFTL.silent
β βββ ...
βββ A0201/
βββ ...
Each silent file holds the 25-decoy ensemble for one peptide-allele pair, with
Rosetta energy scores embedded alongside the coordinates. Paths use
filesystem-safe allele names (A0101/ for HLA-A*01:01) and group files by the
peptide's first residue; metadata.csv carries the standard form (A*01:01) and
a pdb_dir column with the full path for every row.
There is one silent file per pair (112,561); the 118,985 rows exceed this because 6,423 pairs carry both an IC50 and a Kd measurement.
Quickstart
The structures total ~155 GB, so start with metadata.csv (40 MB) and pull only
the silent files you need.
pip install huggingface_hub pandas
1. Get the metadata table.
import pandas as pd
from huggingface_hub import hf_hub_download
path = hf_hub_download("kunikohunter/PepBind3D", "metadata.csv",
repo_type="dataset")
df = pd.read_csv(path)
print(len(df), "measurements over", df[["allele", "peptide"]].drop_duplicates().shape[0], "pairs")
2. Separate quantitative from censored measurements. Roughly 44% of rows are
reported at or above an assay detection ceiling. These are not affinities and
must not be used as numbers: a peptide recorded at 20,000 nM bound too weakly to
measure, so the value is a floor, not a result. They are still information. They
identify peptides that did not bind, which is the label a binder/non-binder model
needs, and I_sc separates them from quantitative binders on its own (AUROC 0.68
for IC50, 0.64 for Kd). Which subset you want depends on the task: exclude the
censored rows when regressing on affinity, keep both when classifying.
CEILINGS = {"IC50": ({20000, 50000, 70000}, 70000),
"Kd": ({5000, 10000, 20000}, 20000)}
def split_by_censoring(df, assay):
"""-> (quantitative affinities, censored non-binders)"""
exact, top = CEILINGS[assay]
sub = df[(df.measurement_type == assay) & ~df.flagged]
censored = sub.measurement_value.isin(exact) | (sub.measurement_value >= top)
return sub[~censored], sub[censored]
ic50, ic50_censored = split_by_censoring(df, "IC50") # 18,113 and 3,114 rows
print(ic50[["allele", "peptide", "measurement_value", "I_sc_best"]].head())
3. Download the structures for one pair. pdb_dir gives the path for every
row.
row = ic50.iloc[0]
silent = hf_hub_download("kunikohunter/PepBind3D", row.pdb_dir, repo_type="dataset")
To pull a whole allele instead, use allow_patterns:
from huggingface_hub import snapshot_download
snapshot_download("kunikohunter/PepBind3D", repo_type="dataset",
allow_patterns="structures/A0201/*")
4. Extract PDB coordinates from a silent file with Rosetta:
extract_pdbs.linuxgccrelease -in:file:silent A0201/G/GILGFVFTL.silent
IEDB Data Curation
Binding affinity data were retrieved from a local copy of the IEDB bulk download
(mhc_ligand_full.csv, accessed April 14, 2025) and processed with a custom
Python pipeline (IEDBTestPipeline.py).
1. Retrieval and Assay Filtering
The full IEDB MHC ligand table was read in chunks and filtered to entries belonging to HLA-A, HLA-B or HLA-C alleles with quantitative binding measurements. Rows were retained only if they reported one of two assay response types:
- Half maximal inhibitory concentration (IC50)
- Dissociation constant (Kd)
Variant labels in the IEDB (dissociation constant KD (~EC50),
dissociation constant KD (~IC50)) were normalized to a single canonical label
(dissociation constant (KD)) prior to filtering. Entries missing either a
quantitative measurement value or assay units were dropped.
2. Per-Allele Deduplication
Records were grouped by allele. Within each allele, duplicate entries for the same epitope (identified by IEDB Epitope IRI) were resolved separately for IC50 and Kd measurements, using the following rules in order:
| Scenario | Action |
|---|---|
| Two entries, one lacks a PubMed ID | Retain the entry with a PubMed ID; drop the other |
| Two entries, both lack PubMed IDs, values differ by β€10 nM | Retain one entry (first occurrence) |
| Two entries, both lack PubMed IDs, values differ by >10 nM | Drop both entries |
| Two entries, both have PubMed IDs, values differ by <10 nM | Retain one entry (first occurrence) |
| Two entries, both have PubMed IDs, values conflict (β₯10 nM difference) | Flag both for manual review |
| More than two entries | Drop entries lacking PubMed IDs first; if >2 remain, retain the entry closest to the median measurement value |
| Any other ambiguous case | Flag for manual review |
Entries that could not be unambiguously resolved were written to a separate
flagged_IEDB_data.csv per allele and excluded from the cleaned dataset. These
are the flagged = True entries in metadata.csv.
3. Sequence-Level Filtering
Peptide sequences containing the + character (used by IEDB to denote
non-canonical or modified amino acids) were excluded from structure generation.
Retained peptides consist of the 20 standard amino acids, 7 to 15 residues long.
Metadata Fields
| Column | Description |
|---|---|
allele_iedb |
Allele name in IEDB format (e.g. HLA-A_01_01) |
allele |
Standard allele notation (e.g. A*01:01) |
allele_compact |
Filesystem-safe allele form used in paths (e.g. A0101) |
peptide |
Peptide amino acid sequence |
peptide_length |
Length of peptide in residues |
measurement_type |
Assay type. Exact string values IC50 or Kd (case-sensitive) |
measurement_value |
Quantitative binding measurement |
measurement_units |
Units of measurement (nM) |
assay_method |
Assay method as reported in IEDB |
assay_response |
Full assay response description from IEDB |
pubmed_id |
PubMed ID of the source publication |
parent_protein |
Source protein of the peptide |
protein_accession |
UniProt/GenBank accession of source protein |
source_organism |
Organism of origin |
source_version |
Internal curation-batch label; carries no meaning for downstream use |
flagged |
Whether the entry was flagged during IEDB data cleaning |
self_templated |
Whether the pair's own crystal structure was available as a threading template. Exclude these when measuring structure-prediction accuracy |
has_structures |
Whether a structural ensemble is available for this pair |
num_pdbs |
Number of decoy structures in the silent file (25) |
I_sc_best |
Best (lowest) interface score across the 25-decoy ensemble (REU). Recommended primary metric - see below |
I_sc_mean |
Mean interface score across the ensemble (REU) |
reweighted_sc_best / reweighted_sc_mean |
Best and mean reweighted score (REU) |
total_score_best / total_score_mean |
Best and mean total_score (REU) |
pep_sc_best / pep_sc_mean |
Best and mean peptide score (REU) |
pdb_dir |
Relative path to the peptide silent file within the dataset |
Which score to use. Each score is summarized as the best (lowest) and mean across the 25-decoy ensemble:
I_sc(interface score) - the peptide-MHC interaction energy in isolation. This is the recommended primary metric; it showed the strongest association with experimental affinity.reweighted_sc(reweighted score) - upweights peptide-relevant energy terms but retains full-pose energy.total_score- the complete Rosetta pose energy. Because it is dominated by the internal energy of the MHC receptor, which varies little among peptides presented by the same allele, it is the least sensitive of the three for ranking binding.
All scores are in Rosetta Energy Units (REU); lower is more favorable. REU is not a binding free energy - these rank poses within a modeling framework and are not thermodynamic quantities.
Computational Methods
Structures were generated with Rosetta FlexPepDock, 25 decoys per pair. Each
peptide was threaded onto a length-matched template from a local MHC template
database (SimpleThreadingMover), trimmed, given its receptor, relaxed
(FastRelax, 5 repeats, ref2015), prepacked, and refined by flexible peptide
docking (-pep_refine -nstruct 25 -ex1 -ex2aro). No score cutoff was applied:
all 25 decoys are retained.
Where an allele had no experimental receptor structure, the Ξ±1/Ξ±2 domains were modeled with AlphaFold2 from the IPD-IMGT/HLA protein alignment.
All structures were generated with Rosetta 2024.09+release.06b3cf8.
FlexPepDock refinement holds the MHC backbone fixed, so decoys within a pair differ only in the peptide; MHC CΞ± coordinates are identical across an ensemble.
Validation
From the accompanying manuscript:
- Structural accuracy. 76 pairs have a matching experimental crystal structure. Measured on ensembles re-docked with self-matching templates excluded, the best-scoring decoy reaches a median peptide-backbone RMSD of 1.21 Γ (IQR 0.93-1.68, 87% within 2 Γ ); the best decoy of each ensemble reaches 0.99 Γ .
- Score-affinity relationship. Spearman Ο between best-decoy
I_scand log affinity is 0.31 (IC50, n = 18,113) and 0.18 (Kd, n = 48,395), censored values excluded. The relationship is real but modest: these scores are intended as input features for a downstream model, not as standalone affinity predictors. - Binder discrimination.
I_scseparates censored from quantitative measurements with AUROC 0.678 (IC50) and 0.639 (Kd), so the censored measurements carry information rather than being merely excluded.
Known Limitations and Caveats
Binding measurements
- IC50 values pile up at 20,000, 50,000 and 70,000 nM, and Kd values at 5,000, 10,000 and 20,000 nM, consistent with assay detection ceilings. Treat these as censored (β₯ the reported value) rather than exact.
- Values above the highest ceiling are censored too, and testing only for the exact ceiling values keeps them: 1,366 IC50 rows sit above 70,000 nM and 8,651 Kd rows above 20,000 nM, including a 1,000,000 nM placeholder used for peptides with no measurable binding. Censored rows are ~44% of the dataset overall, and half of the Kd rows.
- Kd pools three different assays, distinguishable through
assay_method. The competitive radioligand subset is ~1% censored; the two fluorescence subsets are 71-74% censored and centered about one log unit stronger. Stratify onassay_methodor model the censoring explicitly. - IC50 and Kd are not directly comparable and have not been converted between
each other. Both are retained, with
measurement_typerecording which.
Structures
- All structures are computationally generated, and the best-scoring decoy is not guaranteed to be the native-like conformation.
- RMSD values embedded in silent files are computed against the threading template, not against any experimental reference, and are not a measure of model accuracy.
self_templatedmarks 370 pairs (0.33%) whose own crystal structure was in the threading template library, so their structures were built from real coordinates of that exact peptide. They are the most accurate structures here, and they must be excluded when measuring structure-prediction accuracy or the result is inflated.
Coverage
- Allele representation is uneven:
A*02:01alone accounts for 9.2% of pairs, and seven alleles have fewer than five. - HLA-C is included but sparsely sampled (1,861 pairs) and limited to 9- and 10-mer peptides, because the template library holds only 9- and 10-mer HLA-C structures.
- HLA class II alleles are not included, and peptides carrying post-translational modifications or non-standard residues were excluded before structure generation.
Citation
If you use this dataset, please cite:
[Manuscript citation - to be added upon publication]
Dataset DOI: https://doi.org/10.57967/hf/10466
Experimental binding data are sourced from the Immune Epitope Database (IEDB), also available under CC BY 4.0. Please cite IEDB as well:
Vita R, Mahajan S, Overton JA, et al. The Immune Epitope Database (IEDB): 2018 update. Nucleic Acids Research. 2019;47(D1):D339-D343. https://doi.org/10.1093/nar/gky1006
Template and reference structures come from the RCSB PDB (public domain, CC0).
Code
Curation, structure generation and the validation analyses: https://github.com/kunikohunter/PepBind3D (archived at https://doi.org/10.5281/zenodo.22796306)
License
Released under CC BY 4.0: reuse and modification are permitted, including commercially, as long as the dataset is cited.
- Downloads last month
- 2,315